Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia

Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
Carmen QuirósIrene Halperin

Abstract

Since the onset of cross hormone therapy (CHT) in transsexual individuals, there has been concern about possible chronic side effects. Our objective was to assess baseline differences in lipid profile in individuals with gender identity disorder in relation to prior CHT, and changes in the lipid profile and other cardiovascular (CV) risk factors after 24 months of treatment. Retrospective longitudinal study including all individuals assisted for the first time in the Gender Identity Unit of Catalonia from 2006 to 2010. Socio-demographical, anthropometric and laboratory data were collected. We evaluated 247 transsexuals, 150 male to female (MtF: 60.7%) and 97 female to male (FtM; 39.3%). At baseline, FtM transsexuals were younger and had started prior CHT less often than MtF (13.4% vs. 64.7%; p<0.001). During follow up, in MtF weight and BMI increased significantly, as well as systolic and diastolic blood pressure, though these latter remained within normal range. No significant differences in lipid profile were observed. FtM transsexuals also presented an increase in weight and BMI, without differences in blood pressure. A general worsening in lipid profile was observed in this group, with increased total cholesterol (166.0 ± 3...Continue Reading

References

Nov 28, 1997·Clinical Endocrinology·P J van KesterenL J Gooren
Apr 18, 2003·Clinical Endocrinology·Jolanda M H ElbersLouis J G Gooren
Dec 13, 2003·The Journal of Clinical Endocrinology and Metabolism·A W F T TooriansJ Rosing
Aug 4, 2004·European Journal of Internal Medicine·Manuel SosaDiego Hernández
Aug 5, 2004·The Journal of Clinical Endocrinology and Metabolism·David S Guzick
Sep 1, 2006·International Journal of Impotence Research·G M C RosanoM Fini
Nov 8, 2007·The Journal of Clinical Endocrinology and Metabolism·Louis J GoorenMathijs C Bunck
Jan 27, 2011·European Journal of Endocrinology·Henk AsschemanLouis J G Gooren
May 21, 2011·The Journal of Sexual Medicine·Johannes OttUlrike Kaufmann

❮ Previous
Next ❯

Citations

Apr 17, 2016·The Lancet. Diabetes & Endocrinology·Michael S Irwig
Mar 10, 2017·Current Opinion in Endocrinology, Diabetes, and Obesity·Michael S Irwig
Aug 4, 2018·Reviews in Endocrine & Metabolic Disorders·Michael S Irwig
Oct 12, 2018·Endocrine Reviews·Guy T'SjoenVin Tangpricha
Nov 26, 2019·Clinical Endocrinology·Barbara I GulanskiNina S Stachenfeld
Jul 31, 2020·Biology of Sex Differences·Tori Stone, Nina S Stachenfeld
Aug 19, 2020·Journal of Hypertension·Paul J ConnellyChristian Delles
Aug 18, 2021·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M KyinnM S Irwig

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.